

# Niels Abildgaard

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/886258/niels-abildgaard-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79  
papers

1,110  
citations

17  
h-index

31  
g-index

87  
ext. papers

1,446  
ext. citations

4.7  
avg, IF

4.1  
L-index

#	Paper	IF	Citations
79	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e206-e217	21.7	275
78	Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 973-82	21.7	91
77	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 575-80	7.1	60
76	Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. <i>European Journal of Haematology</i> , <b>2016</b> , 97, 303-9	3.8	41
75	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , <b>2021</b> , 35, 31-44	10.7	39
74	A systematic review of health-related quality of life in longitudinal studies of myeloma patients. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 3-17	3.8	38
73	Plasma Cell Leukemia: Definition, Presentation, and Treatment. <i>Current Oncology Reports</i> , <b>2019</b> , 21, 8	6.3	36
72	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e119-e130	21.7	33
71	The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma. <i>Leukemia Research</i> , <b>2015</b> , 39, 971-5	2.7	30
70	The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. <i>Cancer Medicine</i> , <b>2017</b> , 6, 1807-1816	4.8	27
69	The Danish National Multiple Myeloma Registry. <i>Clinical Epidemiology</i> , <b>2016</b> , 8, 583-587	5.9	27
68	A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 153-161	1.9	24
67	Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. <i>European Journal of Haematology</i> , <b>2016</b> , 96, 46-54	3.8	23
66	Trends in hematological cancer in the elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , <b>2016</b> , 55 Suppl 1, 98-107	3.2	22
65	Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. <i>PLoS ONE</i> , <b>2017</b> , 12, e0188988	3.7	19
64	Kind of blue: A systematic review and meta-analysis of music interventions in cancer treatment. <i>Psycho-Oncology</i> , <b>2018</b> , 27, 386-400	3.9	19
63	Multiple Myeloma Associated Bone Disease. <i>Cancers</i> , <b>2020</b> , 12,	6.6	17

62	The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. <i>Leukemia</i> , <b>2019</b> , 33, 546-549	10.7	17
61	High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia. <i>Leukemia Research</i> , <b>2015</b> , 39, 555-60	2.7	16
60	Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2650-9	1.9	16
59	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. <i>Haematologica</i> , <b>2020</b> , 105, 2879-2882	6.6	15
58	Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. <i>Apmis</i> , <b>2015</b> , 123, 652-8	3.4	15
57	Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.. <i>Blood</i> , <b>2009</b> , 114, 530-530	2.2	13
56	Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 11-24	4.5	12
55	LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations. <i>European Journal of Haematology</i> , <b>2016</b> , 97, 175-82	3.8	12
54	Strategies to improve patient-reported outcome completion rates in longitudinal studies. <i>Quality of Life Research</i> , <b>2020</b> , 29, 335-346	3.7	11
53	Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 1977-1982	4.4	10
52	Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 3887-3896	3.9	10
51	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , <b>2021</b> , 8, e934-e946	14.6	9
50	Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 227-234	3.8	9
49	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. <i>Haematologica</i> , <b>2020</b> , 105, 1650-1659	6.6	9
48	Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis. <i>European Journal of Haematology</i> , <b>2015</b> , 95, 211-7	3.8	8
47	Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1824-36	8.8	8
46	Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E611-E614	7.1	8
45	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , <b>2018</b> , 183, 375-384	4.5	7

44	A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. <i>Experimental Hematology and Oncology</i> , <b>2018</b> , 7, 18	7.8	7
43	Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 119-124	4.5	7
42	Classification of Amyloidosis by Model-Assisted Mass Spectrometry-Based Proteomics.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 23,	6.3	6
41	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma. <i>Experimental Hematology</i> , <b>2020</b> , 84, 7-18.e12	3.1	5
40	Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes. <i>Biomarker Research</i> , <b>2018</b> , 6, 21	8	5
39	Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg <i>Blood</i> , <b>2019</b> , 133, 800-808	2.2	5
38	Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154256	3.7	5
37	N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma. <i>Biomarkers in Medicine</i> , <b>2015</b> , 9, 679-89	2.3	4
36	A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group. <i>Blood</i> , <b>2019</b> , 134, 601-601	2.2	4
35	Brain glucose metabolism in patients with newly diagnosed multiple myeloma significantly decreases after high-dose chemotherapy followed by autologous stem cell transplantation. <i>Nuclear Medicine Communications</i> , <b>2020</b> , 41, 288-293	1.6	4
34	Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using F-sodium fluoride PET/CT. <i>Journal of Nuclear Cardiology</i> , <b>2021</b> , 1	2.1	4
33	Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. <i>Leukemia</i> , <b>2018</b> , 32, 2054-2057	10.7	3
32	STAT3 is over-activated within CD163 bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	3
31	Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 70-78	3.8	3
30	Comparison of F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2846-2855	8.8	3
29	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 74	7	2
28	Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy. <i>Journal of the Neurological Sciences</i> , <b>2015</b> , 349, 60-4	3.2	1
27	Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry. <i>Blood</i> , <b>2019</b> , 134, 1849-1849	2.2	1

26	A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support. <i>Blood</i> , <b>2011</b> , 118, 3073-3073	2.2	1
25	Health-Related Quality of Life (HRQoL) Measurements in Multiple Myeloma Patients Obtained By EORTC QLQ-C30; A Critical Review of Interpreting HRQoL Data in Longitudinal Studies. <i>Blood</i> , <b>2016</b> , 128, 540-540	2.2	1
24	Prognostic significance of F-sodium fluoride in newly diagnosed multiple myeloma patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 10, 151-160	2.2	1
23	Correlation of whole-bone marrow dual-time-point F-FDG, as measured by a CT-based method of PET/CT quantification, with response to treatment in newly diagnosed multiple myeloma patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 10, 257-264	2.2	1
22	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 327-336	7.5	1
21	Germline variants at SOHLH2 influence multiple myeloma risk. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 76	7	1
20	Harnessing the Immune System to Fight Multiple Myeloma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
19	Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4. <i>Scientific Reports</i> , <b>2021</b> , 11, 19092	4.9	1
18	Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. <i>European Journal of Haematology</i> , <b>2022</b> , 108, 34-44	3.8	1
17	Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?. <i>Experimental Hematology</i> , <b>2021</b> , 98, 14-24	3.1	0
16	Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma. <i>Leukemia Research</i> , <b>2019</b> , 78, 1-2	2.7	
15	The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey. <i>Blood</i> , <b>2021</b> , 138, 1638-1638	2.2	
14	HGF Inhibits BMP-Induced Osteoblastogenesis: Implications for the Bone Disease in Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 3451-3451	2.2	
13	Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark. <i>Blood</i> , <b>2019</b> , 134, 5030-5030	2.2	
12	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide. <i>Blood</i> , <b>2014</b> , 124, 5702-5702	2.2	
11	Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , <b>2014</b> , 124, 3481-3481	2.2	
10	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. <i>Blood</i> , <b>2015</b> , 126, 4245-4245	2.2	
9	Bone Marrow Microenvironmental Overexpression of DKK1, HGF, Frizzled-Related Protein B, and Syndecan-1 Are Associated with the Degree of Osteolytic Bone Disease in Multiple Myeloma Patients. <i>Blood</i> , <b>2008</b> , 112, 5139-5139	2.2	

8	Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by Bortezomib. <i>Blood</i> , <b>2008</b> , 112, 5183-5183	2.2
7	Multiple Myeloma Plasma Cell Expression of Hepatocyte Growth Factor mRNA Isoforms Correlates with Overall Survival In Myeloma Patients. <i>Blood</i> , <b>2010</b> , 116, 4983-4983	2.2
6	Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma.. <i>Blood</i> , <b>2012</b> , 120, 2922-2922	2.2
5	Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 3977-3977 <sup>2,2</sup>	2.2
4	The impact of changed treatment patterns in multiple myeloma on health-care utilisation and costs, myeloma complications, and survival: A population-based comparison between two time periods in Denmark. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 63-73	3.8
3	Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 4501-4511	3.9
2	Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. <i>Covid</i> , <b>2021</b> , 1, 303-314	3.9
1	Vertebroplasty in patients with multiple myeloma with vertebral compression fractures: protocol for a single-blind randomised controlled trial. <i>BMJ Open</i> , <b>2021</b> , 11, e045854	3